ARA-290

Peptide ARA 290, derived from EPO, is now the subject of research to see whether it can
improve cell survival, control blood pressure, and stimulate blood vessel development, among
other potential advantages.
Studies have shown that this glycoprotein also has a pain-relieving effect and neuroprotective
properties. The ARA-290 phase II clinical studies are now over, and the peptide will soon be
moving on to the phase III clinical trials to understand further how it affects diabetes.

The Maintenance and Defense of Tissues

Studies show that therapy with ARA-290 inhibits macrophage activation, which, according to
research conducted on mice, improves the health of islet cells [i] in the body and ensures their
continued life. Compared to exogenous insulin, the control that islet cells give over blood sugar
is superior, which reduces the number of problems. The study on ARA-290 demonstrates that
this peptide may increase the time that islet cells can survive after transplantation. However,
these cells do not survive transplantation for an extended period.
In addition, research shows that ARA 290 peptide protects against typical inflammatory
reactions and enhances tissue protection. Consequently, this leads to accelerated wound
healing, accelerated repair, and decreased mortality, as shown by studies conducted on
animals.

Avoiding the Spread of Disease

According to studies conducted on mice, administering ARA 290 increases the length of time
cells can survive and makes it possible for endothelial colony-forming cells (ECFCs) to construct
and mend damaged blood arteries in the body. Preventing retinal ischemia, the primary cause of
blindness in industrialized countries, is another benefit of preserving these cells, as per
research.
More recent research suggests that the ARA 290 peptide improves the migration, proliferation,
and overall health of ECFCs while simultaneously targeting parts of the vasculature that need
repair.

Immune System Booster

The results of recent clinical studies suggest that ARA-290 may be able to assist in improving
research subjects’ immune systems.To provide a concise explanation, the tissue-protective receptor, also known as TPR, is
expressed in various immune cells, including dendritic cells, macrophages, mast cells, and
lymphocytes.
According to the findings of several scientific studies, ARA-290 can bind to the TPR found in
immune cells and directly affect the functioning of those cells. When ARA 290 promotes TPR, it
significantly decreases the creation of proinflammatory cytokines such as IL-6. As a result, the
severity of illnesses is mitigated, and new diseases are prevented from developing in the first
place.

Pain Relief

Studies have shown that targeting the innate repair receptor may decrease inflammation and
neuropathic pain. This aspect is even though neuropathic pain is notoriously difficult to treat. It
has been shown, via research conducted on animals, that the administration of ARA-290 can
act on the IRR and suppress TRPV1 activity. The ARA 290 peptide, which treats the pain
associated with multiple sclerosis, diabetes, and amputation, works by acting on this receptor.
Researchers showed this result via studies conducted on animals.
Research shows that the treatment with ARA-290 therapy may also increase the number of tiny
nerve fibers [ii], typically associated with certain autoimmune illnesses. This process can result
in a considerable reduction in the amount of pain experienced. As a result of a study conducted
on animals, many scientists have concluded that ARA-290 might be a helpful therapy for nerve
damage caused by illnesses such as diabetes, celiac disease, thyroid disease, and HIV.